Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET

NCT05050942 is registered in ClinicalTrials.gov with Camurus AB as lead sponsor.

NCT NCT05050942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05050942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
Lead sponsor
Camurus AB
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 22, 2021
Completion date
November 30, 2028
Enrollment
332 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

gastro-enteropancreatic neuroendocrine tumor